Orthopedic Regenerative Surgical Products Global Market Report 2024

Orthopedic regenerative surgical products play a crucial role in treating various musculoskeletal conditions, including joint pains, gout, articular defects, fibromyalgia, osteoarthritis, trauma, joint replacement, and other orthopedic injuries. These products are particularly significant in regenerative orthopedic medicine, where nonsurgical treatments like platelet-rich plasma (PRP) are often chosen to aid in the healing and repair of musculoskeletal injuries, such as those affecting joints, tendons, ligaments, and muscles.

The main types of orthopedic regenerative surgical products include allografts, synthetic materials, cell-based products, and viscosupplements. Allografts involve the transplantation of tissue between genetically distinct individuals of the same species. Examples of human allografts include anterior tibialis tendon, frozen femoral head, freeze-dried bone chips, demineralized bone matrix (DBM) putty, acellular dermis, and amniotic membrane. These regenerative products are utilized by hospitals, ambulatory surgical centers, and other healthcare facilities for the treatment of orthopedic conditions such as pain management, trauma repair, cartilage and tendon repair, and joint reconstruction.

The orthopedic regenerative surgical products market research report is one of a series of new reports that provides orthopedic regenerative surgical products market statistics, including orthopedic regenerative surgical products industry global market size, regional shares, competitors with an orthopedic regenerative surgical products market share, detailed orthopedic regenerative surgical products market segments, market trends and opportunities, and any further data you may need to thrive in the orthopedic regenerative surgical products industry. This orthopedic regenerative surgical products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The orthopedic regenerative surgical products market size has grown strongly in recent years. It will grow from $4.27 billion in 2023 to $4.66 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historic period can be attributed to several factors, including an aging population, orthopedic injuries, increased patient demand, advancements in sports medicine, and the prevalence of musculoskeletal disorders.

The orthopedic regenerative surgical products market size is expected to see strong growth in the next few years. It will grow to $6.4 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the forecast period can be linked to factors such as regulatory approvals, the adoption of sustainable practices, the increasing popularity of minimally invasive procedures, a focus on rehabilitation and physical therapy, and the emphasis on joint preservation. Major trends expected in the forecast period encompass the utilization of advanced biomaterials, ongoing surgical advancements, the integration of artificial intelligence (AI) and predictive analytics, progress in regenerative medicine, and advancements in orthopedic implants.

The increasing prevalence of orthopedic diseases globally is expected to contribute to the growth of the market for orthopedic regenerative surgical products. These products play a crucial role in preventing orthopedic issues such as fractures, sprains, and strains, as well as addressing lifelong conditions associated with ongoing functional limitations and disability. With approximately 1.71 billion people affected by musculoskeletal conditions worldwide, these diseases are a leading cause of disability globally, with low back pain standing out as the primary contributor in 160 countries. Consequently, the rising prevalence of orthopedic diseases is a driving force behind the demand for orthopedic regenerative surgical products.

The anticipated growth of the orthopedic regenerative surgical products market is expected to be propelled by the increasing number of hospitals. Hospitals, as healthcare institutions, are essential in providing medical treatment, care, and services to individuals who are ill or injured. The adoption of orthopedic regenerative surgical products in hospitals is associated with enhanced patient outcomes, reduced risk of complications, faster healing and recovery, and the availability of advanced regenerative surgical options. As of May 2023, the American Hospital Association (AHA) reported an increase in the total number of hospitals to 6,129 compared to 6,093 in 2022, with total admissions across all U.S. hospitals reaching 34,011,386 compared to 33,356,853 in the previous year. Therefore, the growing number of hospitals is a significant factor driving the expansion of the orthopedic regenerative surgical products market.

Technological advancements emerge as a notable trend gaining momentum in the orthopedic regenerative surgical products market. An illustrative example is Anika Therapeutics, Inc., a USA-based company specializing in orthopedic and regenerative medicines. In 2021, the company announced the successful completion of the first human surgical procedure using its injectable hyaluronic acid (HA)-based bone repair therapy. This innovative therapy addresses bone voids and other skeletal system bone defects resulting from trauma or age-related degeneration, benefiting approximately 900,000 people requiring treatment for such conditions in the knee.

Major companies in the orthopedic regenerative surgical products market are strategically focusing on innovative products like the non-permanent ossiofiber compression staple to drive market revenues. This medical device is utilized in orthopedic and musculoskeletal surgeries for fracture fixation and bone fusion, providing temporary stability and compression to support healing and fusion. For instance, Ossio Inc., a US-based company specializing in orthopedic and musculoskeletal applications, launched the non-permanent ossiofiber compression staple in February 2023. Combining mechanical strength and spontaneous bone regeneration, this staple offers an alternative to traditional implants, such as resorbable and allograft options, as well as permanent metal hardware. Ossiofiber Compression Staples provide solutions for various midfoot and hindfoot procedures, including flatfoot corrective procedures, Lapidus fusions, and midfoot fusions.

In 2021, Stryker, a medical technologies corporation based in the US, acquired OrthoSensor Inc. to further enhance its medical and surgical, neurotechnology, and spine offerings aimed at improving patient and hospital outcomes. OrthoSensor Inc. is a US-based company specializing in the digital evolution of musculoskeletal care and sensor technology for total joint replacement.

Major companies operating in the orthopedic regenerative surgical products market include Baxter International Inc., Zimmer Biomet Holdings Inc., Stryker Corporation, Smith&Nephew PLC, Allosource, Anika Therapeutics Inc., Vericel Corporation, Amniox Medical Inc., MIMEDX Group Inc., Aptissen S.A, Arthrex Inc., Bioventus LLC, Conmed Corporation, DePuy Synthes Inc., Exactech Inc., Globus Medical Inc., Integra LifeSciences Corporation, Johnson & Johnson Medical Devices group, Kuros Biosciences AG, Medtronic PLC, NuVasive Inc., Orthofix Medical Inc., Osiris Therapeutics Inc., RTI Surgical Inc., SeaSpine Holdings Corporation, Terumo BCT Inc., Tissue Regenix Group PLC, Wright Medical Group N.V., Xtant Medical Holdings Inc., Camber Spine Technologies, Lima Corporate, Life Spine Inc., CollPlant Biotechnologies Ltd.

North America was the largest region in the orthopedic regenerative surgical products market in 2023 and is also expected to be the fastest-growing region in the forecast period. The regions covered in orthopedic regenerative surgical products market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the orthopedic regenerative surgical products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The orthopedic regenerative surgical products market consists of sales of allograft wedges, allowrap DS, BIO⁴, DBM, hydroset, imbibe, nerve repair, and prochondrix CR.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.